Journal: Cell death and differentiation

Article Title: PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway.

doi: 10.1038/s41418-022-00990-5

Figure Lengend Snippet: Fig. 1 PRMT4 is involved in DIC. NRVMs were treated with DOX (2 μM) for 24, 48, and 72 h. a Representative western blot of PRMT4 was shown; b Quantitative analysis of the protein level of PRMT4. *P < 0.05, #P < 0.01, $P < 0.001; c The mRNA level of PRMT4 was determined; d Representative western blot of PRMT4 in the myocardium 7 days after DOX (15 mg/kg) injection; e Quantitative analysis of the protein level of PRMT4 in DOX-treated hearts. *P < 0.001; NRVMs were infected with adenovirus (Ad-NC, Ad-PRMT4, Ad-shNC, or Ad-shPRMT4) and treated with DOX (2 μM) for 24 h, f–i Adenovirus-mediated PRMT4 overexpression or depletion in vitro was detected by western blot and quantitatively analyzed; Representative images were shown; j, l Cell viability was detected. *P < 0.001, #P < 0.01 (j). *P < 0.001, #P < 0.001 (l); k, m TUNEL positive cells were determined. *P < 0.001, #P < 0.05 (k). *P < 0.001, #P < 0.05 (m). ns, not significant.

Article Snippet: A total of 2 weeks after AAV9 injection, the DIC model was established through a single injection of DOX (15 mg/kg, MedChemExpress).

Techniques: Western Blot, Injection, Infection, Over Expression, In Vitro, TUNEL Assay

Journal: Cell death and differentiation

Article Title: PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway.

doi: 10.1038/s41418-022-00990-5

Figure Lengend Snippet: Fig. 2 PRMT4 overexpression aggravates DIC in vivo. AAV-NC or AAV-PRMT4 were applied via tail vein injection and the DIC model was established 14 days later. a Representative images of M-mode echocardiograms; b Representative Masson staining images. c–e Quantitative analysis of LVEF (c, *P < 0.01, #P < 0.01), FS (d, *P < 0.01, #P < 0.01), and LVEDV (e, *P < 0.05, #P < 0.05) by echocardiography; f–h Quantitative analysis of serum CK-MB (f, *P < 0.001, #P < 0.001), AST (g, *P < 0.001, #P < 0.01), and LDH (h, *P < 0.001, #P < 0.01); i Quantitative analysis of fibrosis area. *P < 0.001, #P < 0.01; j Quantitative analysis of TUNEL positive cells by immunofluorescence staining. *P < 0.001, #P < 0.05.

Article Snippet: A total of 2 weeks after AAV9 injection, the DIC model was established through a single injection of DOX (15 mg/kg, MedChemExpress).

Techniques: Over Expression, In Vivo, Injection, Staining, TUNEL Assay

Journal: Cell death and differentiation

Article Title: PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway.

doi: 10.1038/s41418-022-00990-5

Figure Lengend Snippet: Fig. 3 PRMT4 disruption alleviates DIC in vivo. AAV-shNC or AAV-shPRMT4 were applied via tail vein injection and the DIC model was established 14 days later a Representative images of M-mode echocardiograms; b Representative Masson staining images. c–e Quantitative analysis of LVEF (c, *P < 0.01, #P < 0.05), FS (d, *P < 0.01, #P < 0.05), and LVEDV (e, *P < 0.05, #P < 0.05) by echocardiography; f–h Quantitative analysis of serum CK-MB (f, *P < 0.001, #P < 0.01), AST (g, *P < 0.001, #P < 0.01), and LDH (h, *P < 0.001, #P < 0.01); i Quantitative analysis of fibrosis area, *P < 0.001, #P < 0.001; j Quantitative analysis of TUNEL positive cells by immunofluorescence staining, *P < 0.001, #P < 0.01.

Article Snippet: A total of 2 weeks after AAV9 injection, the DIC model was established through a single injection of DOX (15 mg/kg, MedChemExpress).

Techniques: Disruption, In Vivo, Injection, Staining, TUNEL Assay

Journal: Cell death and differentiation

Article Title: PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway.

doi: 10.1038/s41418-022-00990-5

Figure Lengend Snippet: Fig. 7 PRMT4 transcriptionally controls GPX4 expression through Nrf2. a, b co-IP assay showed the interaction between PRMT4 and Nrf2 in NRVMs; c Cell lysates from NRVMs were incubated with anti-IgG or Nrf2 antibody, and followed by WB with anti-ADMA; d, e NRVMs were transfected with adenovirus, cells were harvested 24 h after DOX treatment and subjected to nuclear-cytoplasmic fractionation. Then, the protein level of Nrf2 in the nucleus and cytoplasm was determined respectively; f Luciferase assay was performed to analyze the effect of PRMT4 on Nrf2-mediated GPX4 promoter activation, *P < 0.001, #P < 0.001, $P < 0.05; g, h H9C2 cells were transfected with adenovirus (Ad-NC, Ad-shNC, Ad-PRMT4, or Ad-shPRMT4) and ChIP assay was used to analyze the enrichment of Nrf2 on the rat GPX4 promoter loci with antibody against IgG or Nrf2. *P < 0.001, #P < 0.01 (g), *P < 0.001, #P < 0.05 (h); i Schematic model of the role and underlying mechanism of PRMT4 in the progression of DIC.

Article Snippet: A total of 2 weeks after AAV9 injection, the DIC model was established through a single injection of DOX (15 mg/kg, MedChemExpress).

Techniques: Expressing, Co-Immunoprecipitation Assay, Incubation, Transfection, Fractionation, Luciferase, Activation Assay

Journal: Pathogens

Article Title: Tulathromycin and Diclazuril Lack Efficacy against Theileria haneyi , but Tulathromycin Is Not Associated with Adverse Clinical Effects in Six Treated Adult Horses

doi: 10.3390/pathogens12030453

Figure Lengend Snippet: Horses utilized in the study and T. haneyi erythrocyte stabilate used for inoculation. PPE = percent parasitized erythrocytes.

Article Snippet: The goal of the present study was to assess the in vivo efficacy of two commercially available, FDA-approved veterinary medications, tulathromycin (Draxxin ® , Zoetis Inc., Kalamazoo, MI, USA) and diclazuril (Protazil, Merck Animal Health, Intervet Inc., Madison, NJ, USA), against T. haneyi .

Techniques: Control

Journal: Pathogens

Article Title: Tulathromycin and Diclazuril Lack Efficacy against Theileria haneyi , but Tulathromycin Is Not Associated with Adverse Clinical Effects in Six Treated Adult Horses

doi: 10.3390/pathogens12030453

Figure Lengend Snippet: Theileria haneyi nested PCR results for horses in Group 2 throughout the experiment, including two-week intervals during diclazuril treatment (Tx). DPI = days post infection.

Article Snippet: The goal of the present study was to assess the in vivo efficacy of two commercially available, FDA-approved veterinary medications, tulathromycin (Draxxin ® , Zoetis Inc., Kalamazoo, MI, USA) and diclazuril (Protazil, Merck Animal Health, Intervet Inc., Madison, NJ, USA), against T. haneyi .

Techniques: Nested PCR, Infection

Journal: Pathogens

Article Title: Tulathromycin and Diclazuril Lack Efficacy against Theileria haneyi , but Tulathromycin Is Not Associated with Adverse Clinical Effects in Six Treated Adult Horses

doi: 10.3390/pathogens12030453

Figure Lengend Snippet: Theileria haneyi nested PCR results for horses in Group 3 throughout the experiment, including two-week intervals during diclazuril treatment (Tx). DPI = days post infection.

Article Snippet: The goal of the present study was to assess the in vivo efficacy of two commercially available, FDA-approved veterinary medications, tulathromycin (Draxxin ® , Zoetis Inc., Kalamazoo, MI, USA) and diclazuril (Protazil, Merck Animal Health, Intervet Inc., Madison, NJ, USA), against T. haneyi .

Techniques: Nested PCR, Infection